# US 2004/0082010 A1 · Neurotrnasmission disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082010 A1
- Document ID: US20040082010A1
- Status: Published application
- Kind: A1
- Application number: 10/311,575
- Filed: 2003-06-06
- Published: 2004-04-29
- Earliest claimed: 2000-06-16
- Assignees: Isis Innovation Limited; Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
- Inventors: Angela Vincent; Werner Hoch
- Web page: https://patentgrep.com/patent/US20040082010A1

## CPC

- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61P 25/00: Drugs for disorders of the nervous system
- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 2333/71: for growth factors; for growth regulators
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

There is disclosed a method for diagnosing neurotransmission or developmental disorders in a mammal comprising the step of detecting in a bodily fluid of said mammal autoantibodies to an epitope of the muscle specific tyrosine kinase (MuSK). One such method comprises a) contacting said bodily fluid with said MuSK or an antigenic determinant thereof; and b) detecting any antibody-antigen complexes formed between said receptor tyrosine kinase or an antigenic fragment thereof and antibodies present in said bodily fluid, wherein the presence of said complexes is indicative of said mammal suffering from said neurotransmission or developmental disorders. Also disclosed are kits for use in the diagnosis of neurotransmission and subsequent developmental disorders.

## Claims

### Claim 1

A method for diagnosing neurotransmission or developmental disorders in a mammal comprising the step of detecting in a bodily fluid of said mammal autoantibodies to an epitope of the muscle specific tyrosine kinase (MuSK).

### Claim 2 (depends on 1)

A method according to claim 1 wherein said method comprises the steps of:
a) contacting said bodily fluid with said MuSK or an antigenic determinant thereof; and
b) detecting any antibody-antigen complexes formed between said receptor tyrosine kinase or an antigenic fragment thereof and antibodies present in said bodily fluid,
wherein the presence of said complexes is indicative of said mammal suffering from said neurotransmission or developmental disorders.

### Claim 3 (depends on 2)

A method according to claim 2 wherein said antibody-antigen complex is detected using an anti-IgG antibody tagged or labelled with a reporter molecule.

### Claim 4 (depends on 3)

A method according to claim 3 wherein said reporter molecule or label includes any of a heavy metal, a fluorescent or luminescent molecule, radioactive or enzymatic tag.

### Claim 5 (depends on 4)

A method according to claim 4 wherein said enzymatic tag comprises horseradish peroxidase-protein A followed by reaction with o-phenylenediamine for subsequent measurement at A492.

### Claim 6 (depends on 3, 4, 5)

A method according to any of claims 3 to 5 whereby the intensity of the signal from the anti-human IgG antibody is indicative of the relative amount of the anti-MuSK autoantibody in the bodily fluid when compared to a positive and negative control reading.

### Claim 7 (depends on 1)

A method according to claim 1 comprising contacting MuSK or an epitope or antigenic determinant thereof having a suitable label thereon, with said bodily fluid, immunoprecipitating any antibodies from said bodily fluid and montitoring for said label on any of said antibodies, wherein the presence of said label is indicative of said mammal is suffering from said neurotransmission or developmental disorder.

### Claim 8 (depends on 7)

A method according to claim 7 wherein said label is a radioactive label.

### Claim 9 (depends on 8)

A method according to claim 8 wherein said label is 125I.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A method according to any of claims 1 to 9 wherein said neurotransmission disorder is Myasthenia gravis.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A method according to any of claims 1 to 9 wherein said developmental disorder is muscle paralysis and/or fixed points in offspring due to maternal antibodies to MuSK.

### Claim 12

An assay kit for diagnosing neurotransmission disorders in mammals comprising MuSK or an epitope thereof and means for contacting said MuSK with a bodily fluid from a mammal.

### Claim 13 (depends on 12)

An assay kit according to claim 12 for detecting Myasthenia gravis.

### Claim 14

An isolated or purified antibody specific for an anti-MuSK autoantibody from a bodily fluid of a mammal.

### Claim 15 (depends on 14)

An isolated or purified antibody according to claim 14 for use in a method of treatment of the human or animal body.

### Claim 16 (depends on 14)

Use of an antibody according to claim 14 in the manufacture of a medicament for the treatment of neurotransmission disorders in a mammal.

### Claim 17 (depends on 16)

Use according to claim 16 wherein said neurotransmission disorder is Myasthenia gravis.

### Claim 18 (depends on 14)

A pharmaceutical composition comprising an antibody according to claim 14 together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

### Claim 19 (depends on 14)

A diagnostic kit for detecting neurotransmission disorders in mammals comprising an antibody according to claim 14 and means for contacting said antibody with a bodily fluid of said mammal.

### Claim 20 (depends on 19)

A kit according to claim 19 wherein said antibody is conjugated to a reporter molecule.

### Claim 21 (depends on 19, 20)

A kit according to claim 19 or 20 wherein said neurotransmission disorder is Myasthenia gravis.

### Claim 22 (depends on 12)

An assay kit according to claim 12 wherein said MuSK or epitope thereof has a revealing label thereon.

### Claim 23 (depends on 22)

An assay kit according to claim 22 wherein said label is 125I.

### Claim 24 (depends on 14)

A method of treating a patient suffering from a neurotransmission disorder comprising administering to said patient an effective amount of an antibody according to claim 14.

### Claim 25 (depends on 24)

A method according to claim 24 wherein said neurotransmission disorder is Myasthenia gravis.

### Claim 26

A method for making a pharmaceutical formulation for the treatment of neurotransmission disorders, comprising the steps of generating and subsequently isolating an antibody specific for anti-MuSK autoantibody from a bodily fluid of a mammal, manufacturing bulk quantities of said antibody and formulating the antibody in a compound including a pharmaceutically acceptable carrier, diluent or excipient therefor.

### Claim 27

A method of identifying compounds capable of alleviating or treating neurotransmission disorders, comprising the steps of contacting a candidate compound in the presence of MuSK or an epitope thereof and an antibody capable of binding MuSK, wherein a compound that prevents binding of said antibody to MuSK or an epitope thereof is a candidate for treating neurotransmission disorders.
